Epetraborole

Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research[1][2][3].

Product Specifications

CAS Number

[1093643-37-8]

Product Name Alternative

GSK-2251052; AN 3365

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Aminoacyl-tRNA Synthetase; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/epetraborole.html

Solubility

10 mM in DMSO

Smiles

OCCCOC1=C2C([C@H](OB2O)CN)=CC=C1

Molecular Formula

C11H16BNO4

Molecular Weight

237.06

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57 (5) :2401-4.|[2]O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59 (1) :289-98.|[3]Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52.